BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12586133)

  • 1. Influence of abciximab on the adhesion of platelets on a shielded plasma gradient prepared on polyethylene.
    Spijker HT; Busscher HJ; van Oeveren W
    Thromb Res; 2002 Oct; 108(1):57-62. PubMed ID: 12586133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
    Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
    J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-dependent effect of abciximab on platelets and neutrophils in a model of cardiopulmonary bypass.
    Asberg AE; Videm V
    Perfusion; 2006 Nov; 21(6):343-52. PubMed ID: 17312858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
    Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
    Tam SH; Sassoli PM; Jordan RE; Nakada MT
    Circulation; 1998 Sep; 98(11):1085-91. PubMed ID: 9736595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA; Lance ET; Damaraju L; Wagner CL; Weisman HF; Jordan RE
    Circulation; 1998 May; 97(17):1680-8. PubMed ID: 9591761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet adhesion and activation on a shielded plasma gradient prepared on polyethylene.
    Spijker HT; Bos R; Busscher HJ; van Kooten T; van Oeveren W
    Biomaterials; 2002 Feb; 23(3):757-66. PubMed ID: 11771696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.